Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TCRX

Tscan Therapeutics Inc

Dec 01 • 04:00PM ET

6.48

Dollar change -0.05
Percentage change -0.77	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.46	Insider Own	11.58%	Shs Outstand	43.55M	Perf Week	26.56%
Market Cap	282.20M	Forward P/E	-	EPS next Y	-1.22	Insider Trans	0.76%	Shs Float	38.50M	Perf Month	79.01%
Income	-88.33M	PEG	-	EPS next Q	-0.29	Inst Own	60.81%	Short Float / Ratio	1.08% / 3.64	Perf Quarter	163.41%
Sales	16.93M	P/S	16.67	EPS this Y	44.00%	Inst Trans	-0.43%	Short Interest	0.42M	Perf Half Y	130.60%
Book/sh	3.53	P/B	1.83	EPS next Y	20.56%	ROA	-38.67%	Target Price	10.60	Perf Year	208.57%
Cash/sh	4.95	P/C	1.31	EPS next 5Y	-	ROE	-61.85%	52W Range	1.45 - 7.15	Perf YTD	318.06%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-35.27%	52W High	-9.37%	Beta	0.82
Dividend %	-	Quick Ratio	6.56	Sales past 5Y	289.37%	Gross Margin	67.14%	52W Low	346.90%	ATR	0.62
Employees	137	Current Ratio	6.56	Sales Q/Q	15.58%	Oper. Margin	-535.94%	RSI (14)	71.12	Volatility	15.47% 14.13%
Optionable	No	Debt/Eq	0.51	EPS Q/Q	64.06%	Profit Margin	-521.63%	Rel Volume	1.42	Prev Close	6.53
Shortable	Yes	LT Debt/Eq	0.48	Earnings	Nov 09 BMO	Payout	-	Avg Volume	114.45K	Price	6.48
Recom	1.17	SMA20	34.99%	SMA50	69.23%	SMA200	125.47%	Volume	162,850	Change	-0.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-22-23	Initiated	Wedbush	Outperform	$8

Dec-01-23 09:55AM	Does TScan Therapeutics, Inc. (TCRX) Have the Potential to Rally 62.33% as Wall Street Analysts Expect? (Zacks)
Nov-30-23 07:00AM	TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years (GlobeNewswire) +12.98%
Nov-27-23 12:00PM	TScan Therapeutics, Inc. (TCRX) is a Great Momentum Stock: Should You Buy? (Zacks)
Nov-20-23 08:50AM	TScan Therapeutics, Inc. (TCRX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -13.83%
Nov-15-23 12:00PM	What Makes TScan Therapeutics, Inc. (TCRX) a New Buy Stock (Zacks)
09:55AM	Loading…
09:55AM	Wall Street Analysts Predict a 125% Upside in TScan Therapeutics, Inc. (TCRX): Here's What You Should Know (Zacks)
Nov-09-23 08:25AM	TScan Therapeutics Inc (TCRX) Reports Q3 2023 Financial Results and Corporate Updates (GuruFocus.com)
07:00AM	TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-23 07:00AM	TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting (GlobeNewswire) +11.03%
Nov-02-23 09:05AM	TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) +7.73%
Oct-12-23 12:00PM	TScan Therapeutics, Inc. (TCRX) Upgraded to Strong Buy: Here's Why (Zacks)
Sep-27-23 09:06AM	TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-12-23 08:00AM	Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors (GlobeNewswire)
Sep-05-23 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-29-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME (GlobeNewswire) +10.96%
12:00PM	Loading…
Aug-16-23 12:00PM	TScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-10-23 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-13-23 07:25AM	Shareholders in TScan Therapeutics (NASDAQ:TCRX) are in the red if they invested a year ago (Simply Wall St.)
Jun-29-23 07:00AM	TScan Therapeutics Announces Transition of Chief Financial Officer (GlobeNewswire)
Jun-15-23 07:42AM	Favourable Signals For TScan Therapeutics: Numerous Insiders Acquired Stock \ (Simply Wall St.)
Jun-06-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors (GlobeNewswire)
Jun-01-23 04:10PM	TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
04:05PM	TScan Therapeutics Announces Closing of Public Offering (GlobeNewswire)
07:00AM	TScan Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-26-23 12:37AM	TScan Therapeutics Announces Pricing of $140 Million Public Offering (GlobeNewswire) +31.28%
May-25-23 04:06PM	TScan Therapeutics Announces Launch of Proposed Public Offering (GlobeNewswire)
May-24-23 04:13PM	TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors (GlobeNewswire)
May-17-23 04:35PM	TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients (Benzinga) -10.53%
07:00AM	TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting (GlobeNewswire)
07:33AM	Loading…
May-11-23 07:33AM	Institutional investors control 30% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 112% (Simply Wall St.) -7.22%
May-10-23 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +42.65%
07:00AM	TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 01:29PM	Why Are TScan Therapeutics Shares Are Shooting Higher Today (Benzinga) +51.14%
09:00AM	Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohns Disease (GlobeNewswire)
May-02-23 04:42PM	TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire) +26.22%
Apr-10-23 07:00AM	TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors (GlobeNewswire)
Mar-31-23 08:00AM	TScan Therapeutics Announces CEO Transition (GlobeNewswire) -18.29%
Mar-14-23 07:00AM	TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies (GlobeNewswire)
Mar-13-23 04:05PM	TScan Therapeutics to Participate in the Barclays Global Healthcare Conference (GlobeNewswire) -13.31%
Mar-10-23 05:12AM	TScan Therapeutics Full Year 2022 Earnings: Misses Expectations (Simply Wall St.)
Mar-08-23 07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones (GlobeNewswire)
Mar-01-23 07:00AM	TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire) +6.78%
Feb-21-23 07:00AM	TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Jan-23-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors (GlobeNewswire)
Jan-20-23 05:35AM	Shareholders in TScan Therapeutics (NASDAQ:TCRX) are in the red if they invested a year ago (Simply Wall St.)
Jan-05-23 07:00AM	TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress (GlobeNewswire)
Dec-12-22 07:00AM	TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022 (GlobeNewswire)
Dec-09-22 06:09AM	A number of insiders bought TScan Therapeutics, Inc. (NASDAQ:TCRX) stock last year, which is great news for shareholders (Simply Wall St.)
Dec-01-22 08:00AM	TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe (GlobeNewswire)
Nov-22-22 07:00AM	TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-11-22 07:00AM	TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) +7.81%
Nov-09-22 07:00AM	TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 07:00AM	TScan Therapeutics Announces Upcoming Virtual Investor Event (GlobeNewswire)
Nov-03-22 09:34AM	TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) +8.65%
Oct-05-22 08:33AM	TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-28-22 09:21AM	Chinese Billionaire Zhang Lei is Selling These 10 Stocks (Insider Monkey)
Sep-22-22 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -8.28%
Sep-12-22 07:00AM	TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures (GlobeNewswire)
Sep-07-22 07:00AM	TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire) +12.12%
Aug-13-22 08:14AM	TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates (Simply Wall St.)
Aug-12-22 06:08AM	New Forecasts: Here's What Analysts Think The Future Holds For TScan Therapeutics, Inc. (NASDAQ:TCRX) (Simply Wall St.) -5.41%
Aug-10-22 07:00AM	TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress (GlobeNewswire) -9.88%
Aug-05-22 11:58AM	Shareholders in TScan Therapeutics (NASDAQ:TCRX) are in the red if they invested a year ago (Simply Wall St.)
Aug-03-22 07:00AM	TScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-11-22 07:00AM	TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology (GlobeNewswire)
Jul-07-22 07:00AM	TScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officer (GlobeNewswire)
Jul-06-22 08:28AM	Is TScan Therapeutics (NASDAQ:TCRX) In A Good Position To Invest In Growth? (Simply Wall St.)
Jun-22-22 07:00AM	TScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium (GlobeNewswire) +5.28%
Jun-02-22 07:00AM	TScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-31-22 07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies (GlobeNewswire)
May-22-22 08:03AM	Insider Buying: The TScan Therapeutics, Inc. (NASDAQ:TCRX) President Just Bought 17% More Shares (Simply Wall St.)
May-19-22 07:00AM	TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting (GlobeNewswire) -14.80%
May-17-22 07:00AM	TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire) +15.94%
May-12-22 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual Meeting (GlobeNewswire)
May-09-22 07:00AM	TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones (GlobeNewswire) -8.33%
May-05-22 10:25AM	TScan Therapeutics, Inc.'s (NASDAQ:TCRX) recent US$6.0m market cap decline means a loss of US$233k for insiders who bought this year (Simply Wall St.) -7.54%
May-02-22 05:02PM	TScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
Apr-11-22 07:00AM	TScan Therapeutics Appoints Leiden Dworak, CPA, MBA, as Vice President, Finance (GlobeNewswire) +17.83%
Mar-09-22 07:00AM	TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities (GlobeNewswire) +5.41%
Mar-02-22 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-18-22 12:39PM	Do Institutions Own TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares? (Simply Wall St.)
Feb-10-22 07:00AM	TScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-24-22 12:30PM	FDA Gives Nod To TScan Therapeutics' Early-Stage Trial Of TSC-100 In Hematologic Malignancies (Benzinga) -5.21%
07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies (GlobeNewswire)
Jan-10-22 07:00AM	TScan Outlines 2022 Priorities as Programs Enter Clinic (GlobeNewswire) -8.30%
Dec-20-21 01:36PM	We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate (Simply Wall St.) -6.39%
Dec-13-21 09:16AM	TScan Therapeutics Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-03-21 07:00AM	TScan Therapeutics to Host a Virtual Event to Discuss Highlights from the 63rd ASH Annual Meeting and Exposition (GlobeNewswire)
Dec-02-21 07:00AM	TScan Therapeutics Establishes Facility to Manufacture T Cell Receptor Engineered T Cell Therapies (GlobeNewswire) -5.70%
Nov-11-21 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-10-21 07:00AM	TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Nov-04-21 09:30AM	TScan Therapeutics Announces Upcoming Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Nov-01-21 09:11AM	Wall Street Analysts Believe TScan Therapeutics, Inc. (TCRX) Could Rally 147%: Here's is How to Trade (Zacks) -5.02%
Oct-19-21 02:43PM	Great news for TScan Therapeutics, Inc. (NASDAQ:TCRX): Insiders acquired stock in large numbers last year (Simply Wall St.) +10.86%
Oct-15-21 10:56AM	Wall Street Analysts See a 215% Upside in TScan Therapeutics, Inc. (TCRX): Can the Stock Really Move This High? (Zacks)
Oct-05-21 07:00AM	TScan Therapeutics Appoints Heather Savelle as Vice President, Investor Relations (GlobeNewswire)
Sep-28-21 07:00AM	TScan Therapeutics to Participate in the Chardan 5th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-09-21 04:05PM	TScan Therapeutics Appoints Zoran Zdraveski, J.D., Ph.D. as Chief Legal Officer (GlobeNewswire)
Sep-02-21 07:00AM	TScan Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire)

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BARBERICH TIMOTHY J	Director	Jun 02	Buy	2.63	37,880	99,564	37,880	Jun 06 07:53 PM
Lynx1 Capital Management LP	10% Owner	May 31	Sale	2.52	25,400	63,952	5,224,600	Jun 02 05:35 PM
Silver Brian M.	Chief Financial Officer	Dec 28	Buy	1.56	3,158	4,941	32,885	Dec 29 02:34 PM
Silver Brian M.	Chief Financial Officer	Dec 27	Buy	1.50	2,842	4,276	29,727	Dec 29 02:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TCRX

Tscan Therapeutics Inc

Upgrade your FINVIZ experience